Comparative Pharmacology
Head-to-head clinical analysis: ARIKAYCE KIT versus DOW ISONIAZID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARIKAYCE KIT versus DOW ISONIAZID.
ARIKAYCE KIT vs DOW-ISONIAZID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amikacin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis.
Inhibits mycolic acid synthesis in Mycobacterium tuberculosis by targeting InhA, a NADH-dependent enoyl-acyl carrier protein reductase, leading to bacterial cell wall disruption.
590 mg (contents of one kit) administered as inhalation via the Lamira Nebulizer System once daily.
300 mg orally once daily, or 5 mg/kg (max 300 mg) daily; alternatively, 15 mg/kg (max 900 mg) orally twice weekly directly observed therapy.
None Documented
None Documented
The terminal elimination half-life of amikacin from plasma is approximately 2-3 hours in patients with normal renal function. In the liposomal formulation (ARIKAYCE), after inhalation, the half-life in epithelial lining fluid is prolonged, with a terminal half-life of approximately 23 hours. Clinical context: accumulation may occur with renal impairment.
Fast acetylators: 0.5–2 hours (mean 1.1 h); slow acetylators: 2–5 hours (mean 3 h). Clinical context: Determines dosing interval; slow acetylators at higher risk of peripheral neuropathy.
Amikacin is primarily eliminated unchanged by glomerular filtration; renal excretion accounts for approximately 94-98% of the dose within 24 hours. Biliary/fecal elimination is minimal (<1%).
Renal: 75–95% (isoniazid and metabolites, primarily acetylisoniazid and isonicotinic acid); fecal <10%; biliary excretion minimal.
Category C
Category A/B
Antimycobacterial
Antimycobacterial